

# Jerome Sarris

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2053987/publications.pdf>

Version: 2024-02-01

154  
papers

9,768  
citations

50170

46  
h-index

43802

91  
g-index

159  
all docs

159  
docs citations

159  
times ranked

10732  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. <i>Lancet Psychiatry</i> , 2019, 6, 675-712.	3.7	815
2	The efficacy of smartphone-based mental health interventions for depressive symptoms: a meta-analysis of randomized controlled trials. <i>World Psychiatry</i> , 2017, 16, 287-298.	4.8	755
3	Can smartphone mental health interventions reduce symptoms of anxiety? A meta-analysis of randomized controlled trials. <i>Journal of Affective Disorders</i> , 2017, 218, 15-22.	2.0	552
4	A meta-review of "lifestyle psychiatry": the role of exercise, smoking, diet and sleep in the prevention and treatment of mental disorders. <i>World Psychiatry</i> , 2020, 19, 360-380.	4.8	424
5	Nutritional medicine as mainstream in psychiatry. <i>Lancet Psychiatry</i> , 2015, 2, 271-274.	3.7	375
6	Herbal medicine for depression, anxiety and insomnia: A review of psychopharmacology and clinical evidence. <i>European Neuropsychopharmacology</i> , 2011, 21, 841-860.	0.3	372
7	Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses. <i>American Journal of Psychiatry</i> , 2016, 173, 575-587.	4.0	315
8	The Effects of Dietary Improvement on Symptoms of Depression and Anxiety: A Meta-Analysis of Randomized Controlled Trials. <i>Psychosomatic Medicine</i> , 2019, 81, 265-280.	1.3	312
9	A systematic review of insomnia and complementary medicine. <i>Sleep Medicine Reviews</i> , 2011, 15, 99-106.	3.8	280
10	Lifestyle medicine for depression. <i>BMC Psychiatry</i> , 2014, 14, 107.	1.1	265
11	The "online brain": how the Internet may be changing our cognition. <i>World Psychiatry</i> , 2019, 18, 119-129.	4.8	248
12	Omega-3 for Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 81-86.	1.1	218
13	The effects of dietary and nutrient interventions on arterial stiffness: a systematic review. <i>American Journal of Clinical Nutrition</i> , 2011, 93, 446-454.	2.2	144
14	The efficacy and safety of nutrient supplements in the treatment of mental disorders: a meta-review of meta-analyses of randomized controlled trials. <i>World Psychiatry</i> , 2019, 18, 308-324.	4.8	139
15	Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review. <i>BMC Psychiatry</i> , 2020, 20, 24.	1.1	130
16	Herbal medicines in the treatment of psychiatric disorders: a systematic review. <i>Phytotherapy Research</i> , 2007, 21, 703-716.	2.8	123
17	Kava: A Comprehensive Review of Efficacy, Safety, and Psychopharmacology. <i>Australian and New Zealand Journal of Psychiatry</i> , 2011, 45, 27-35.	1.3	122
18	Herbal medicines in the treatment of psychiatric disorders: 10-year updated review. <i>Phytotherapy Research</i> , 2018, 32, 1147-1162.	2.8	120

#	ARTICLE	IF	CITATIONS
19	International Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder. <i>Psychotherapy and Psychosomatics</i> , 2019, 88, 263-273.	4.0	114
20	Plant-Based Medicines for Anxiety Disorders, Part 2: A Review of Clinical Studies with Supporting Preclinical Evidence. <i>CNS Drugs</i> , 2013, 27, 301-319.	2.7	111
21	Do long-chain n-3 fatty acids reduce arterial stiffness? A meta-analysis of randomised controlled trials. <i>British Journal of Nutrition</i> , 2011, 106, 974-980.	1.2	107
22	Kava and St. John's Wort: Current Evidence for Use in Mood and Anxiety Disorders. <i>Journal of Alternative and Complementary Medicine</i> , 2009, 15, 827-836.	2.1	105
23	Diet as a hot topic in psychiatry: a population-scale study of nutritional intake and inflammatory potential in severe mental illness. <i>World Psychiatry</i> , 2018, 17, 365-367.	4.8	102
24	The Cognitive-Enhancing Effects of Bacopa monnieri: A Systematic Review of Randomized, Controlled Human Clinical Trials. <i>Journal of Alternative and Complementary Medicine</i> , 2012, 18, 647-652.	2.1	100
25	Kava in the Treatment of Generalized Anxiety Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 643-648.	0.7	99
26	Kava for the Treatment of Generalized Anxiety Disorder RCT: Analysis of Adverse Reactions, Liver Function, Addiction, and Sexual Effects. <i>Phytotherapy Research</i> , 2013, 27, 1723-1728.	2.8	81
27	International Society for Nutritional Psychiatry Research consensus position statement: nutritional medicine in modern psychiatry. <i>World Psychiatry</i> , 2015, 14, 370-371.	4.8	81
28	N-Acetyl Cysteine in the Treatment of Obsessive Compulsive and Related Disorders: A Systematic Review. <i>Clinical Psychopharmacology and Neuroscience</i> , 2015, 13, 12-24.	0.9	78
29	GABA-modulating phytochemicals for anxiety: A systematic review of preclinical and clinical evidence. <i>Phytotherapy Research</i> , 2018, 32, 3-18.	2.8	78
30	The Validity and Value of Self-reported Physical Activity and Accelerometry in People With Schizophrenia: A Population-Scale Study of the UK Biobank. <i>Schizophrenia Bulletin</i> , 2018, 44, 1293-1300.	2.3	77
31	A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression: mitochondrial agents, N-acetylcysteine, and placebo. <i>BMC Medicine</i> , 2019, 17, 18.	2.3	73
32	Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants. <i>Psychopharmacology</i> , 2021, 238, 341-354.	1.5	70
33	Adjuvant use of nutritional and herbal medicines with antidepressants, mood stabilizers and benzodiazepines. <i>Journal of Psychiatric Research</i> , 2010, 44, 32-41.	1.5	69
34	Adjunctive nutraceuticals with standard pharmacotherapies in bipolar disorder: a systematic review of clinical trials. <i>Bipolar Disorders</i> , 2011, 13, 454-465.	1.1	69
35	Major depressive disorder and nutritional medicine: a review of monotherapies and adjuvant treatments. <i>Nutrition Reviews</i> , 2009, 67, 125-131.	2.6	64
36	What Is the Role of Dietary Inflammation in Severe Mental Illness? A Review of Observational and Experimental Findings. <i>Frontiers in Psychiatry</i> , 2019, 10, 350.	1.3	64

#	ARTICLE	IF	CITATIONS
37	Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties. <i>Journal of Translational Medicine</i> , 2020, 18, 374.	1.8	63
38	Complementary medicines (herbal and nutritional products) in the treatment of Attention Deficit Hyperactivity Disorder (ADHD): A systematic review of the evidence. <i>Complementary Therapies in Medicine</i> , 2011, 19, 216-227.	1.3	62
39	Grip Strength Is Associated With Cognitive Performance in Schizophrenia and the General Population: A UK Biobank Study of 476559 Participants. <i>Schizophrenia Bulletin</i> , 2018, 44, 728-736.	2.3	62
40	Nutritional Deficiencies and Clinical Correlates in First-Episode Psychosis: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2018, 44, 1275-1292.	2.3	61
41	Multiple lifestyle factors and depressed mood: a cross-sectional and longitudinal analysis of the UK Biobank (N=84,860). <i>BMC Medicine</i> , 2020, 18, 354.	2.3	60
42	Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca. <i>Journal of Psychopharmacology</i> , 2020, 34, 1125-1133.	2.0	60
43	N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study. <i>CNS Drugs</i> , 2015, 29, 801-809.	2.7	59
44	Ziziphus spinosa seeds for insomnia: A review of chemistry and psychopharmacology. <i>Phytomedicine</i> , 2017, 34, 38-43.	2.3	58
45	Association Between Muscular Strength and Cognition in People With Major Depression or Bipolar Disorder and Healthy Controls. <i>JAMA Psychiatry</i> , 2018, 75, 740.	6.0	54
46	Plant-Based Medicines for Anxiety Disorders, Part 1. <i>CNS Drugs</i> , 2013, 27, 207-219.	2.7	53
47	S-adenosyl methionine (SAME) versus escitalopram and placebo in major depression RCT: Efficacy and effects of histamine and carnitine as moderators of response. <i>Journal of Affective Disorders</i> , 2014, 164, 76-81.	2.0	53
48	Nutraceuticals in the treatment of Obsessive Compulsive Disorder (OCD): A review of mechanistic and clinical evidence. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 887-895.	2.5	50
49	Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 424-455.	1.3	49
50	Complementary medicine, self-help, and lifestyle interventions for Obsessive Compulsive Disorder (OCD) and the OCD spectrum: A systematic review. <i>Journal of Affective Disorders</i> , 2012, 138, 213-221.	2.0	46
51	Influence of Context and Setting on the Mental Health and Wellbeing Outcomes of Ayahuasca Drinkers: Results of a Large International Survey. <i>Frontiers in Pharmacology</i> , 2021, 12, 623979.	1.6	45
52	Handgrip Strength Is Associated With Hippocampal Volume and White Matter Hyperintensities in Major Depression and Healthy Controls: A UK Biobank Study. <i>Psychosomatic Medicine</i> , 2020, 82, 39-46.	1.3	44
53	Lifestyle medicine for depression: A meta-analysis of randomized controlled trials. <i>Journal of Affective Disorders</i> , 2021, 284, 203-216.	2.0	43
54	Kava hepatotoxicity solution: A six-point plan for new kava standardization. <i>Phytomedicine</i> , 2011, 18, 96-103.	2.3	42

#	ARTICLE	IF	CITATIONS
55	Nutraceuticals for major depressive disorder- more is not merrier: An 8-week double-blind, randomised, controlled trial. <i>Journal of Affective Disorders</i> , 2019, 245, 1007-1015.	2.0	42
56	Kava hepatotoxicity in traditional and modern use: the presumed Pacific kava paradox hypothesis revisited. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 170-174.	1.1	41
57	A Review of the Conceptualisation and Risk Factors Associated with Treatment-Resistant Depression. <i>Depression Research and Treatment</i> , 2017, 2017, 1-10.	0.7	40
58	Design and rationale of a 16-week adjunctive randomized placebo-controlled trial of mitochondrial agents for the treatment of bipolar depression. <i>Revista Brasileira De Psiquiatria</i> , 2015, 37, 03-12.	0.9	38
59	Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression. <i>Human Psychopharmacology</i> , 2013, 28, 516-522.	0.7	36
60	Yoga for depression and anxiety symptoms in people with cancer: A systematic review and meta-analysis. <i>Psycho-Oncology</i> , 2021, 30, 1196-1208.	1.0	36
61	N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms. <i>BMC Psychiatry</i> , 2016, 16, 320.	1.1	34
62	L-theanine in the adjunctive treatment of generalized anxiety disorder: A double-blind, randomised, placebo-controlled trial. <i>Journal of Psychiatric Research</i> , 2019, 110, 31-37.	1.5	34
63	St. John's Wort for the Treatment of Psychiatric Disorders. <i>Psychiatric Clinics of North America</i> , 2013, 36, 65-72.	0.7	33
64	Ayahuasca use and reported effects on depression and anxiety symptoms: An international cross-sectional study of 11,912 consumers. <i>Journal of Affective Disorders Reports</i> , 2021, 4, 100098.	0.9	31
65	Integrative Mental Health (IMH): Paradigm, Research, and Clinical Practice. <i>Explore: the Journal of Science and Healing</i> , 2012, 8, 50-57.	0.4	30
66	Polyunsaturated fatty acids and suicide risk in mood disorders: A systematic review. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 74, 43-56.	2.5	30
67	Nutritional Psychiatry: From Concept to the Clinic. <i>Drugs</i> , 2019, 79, 929-934.	4.9	30
68	Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 493.	0.7	29
69	Adjunctive S-adenosylmethionine (SAME) in treating non-remittent major depressive disorder: An 8-week double-blind, randomized, controlled trial. <i>European Neuropsychopharmacology</i> , 2018, 28, 1126-1136.	0.3	29
70	Improvement of cognitive function in schizophrenia with N-acetylcysteine: A theoretical review. <i>Nutritional Neuroscience</i> , 2020, 23, 139-148.	1.5	29
71	A Randomized Controlled Trial Investigating the Effects of a Special Extract of Bacopa monnieri (CDRI Tj ETQq1 1 (ANZCTRN12612000827831). <i>Nutrients</i> , 2015, 7, 9931-9945.	1.7	28
72	Re-introduction of Kava (Piper methysticum) to the EU: Is There a Way Forward?. <i>Planta Medica</i> , 2011, 77, 107-110.	0.7	27

#	ARTICLE	IF	CITATIONS
73	St John's Wort ( <i>Hypericum perforatum</i> ) versus Sertraline and Placebo in Major Depressive Disorder: Continuation Data from a 26-Week RCT. <i>Pharmacopsychiatry</i> , 2012, 45, 275-278.	1.7	27
74	Contaminant Hepatotoxins as Culprits for Kava Hepatotoxicity – Fact or Fiction?. <i>Phytotherapy Research</i> , 2013, 27, 472-474.	2.8	27
75	Herbal medicine use behaviour in Australian adults who experience anxiety: a descriptive study. <i>BMC Complementary and Alternative Medicine</i> , 2016, 16, 60.	3.7	27
76	Kava, the anxiolytic herb: back to basics to prevent liver injury?. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 445-448.	1.1	26
77	The acute effects of kava and oxazepam on anxiety, mood, neurocognition; and genetic correlates: a randomized, placebo-controlled, double-blind study. <i>Human Psychopharmacology</i> , 2012, 27, 262-269.	0.7	26
78	St. John's wort and Kava in treating major depressive disorder with comorbid anxiety: a randomised double-blind placebo-controlled pilot trial. <i>Human Psychopharmacology</i> , 2009, 24, 41-48.	0.7	24
79	Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm. <i>Australian and New Zealand Journal of Psychiatry</i> , 2021, 55, 1127-1133.	1.3	24
80	Current challenges in appraising complementary medicine evidence. <i>Medical Journal of Australia</i> , 2012, 196, 310-311.	0.8	23
81	Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 288-297.	1.3	22
82	Bipolar Disorder and Complementary Medicine: Current Evidence, Safety Issues, and Clinical Considerations. <i>Journal of Alternative and Complementary Medicine</i> , 2011, 17, 881-890.	2.1	21
83	Escitalopram Efficacy in Depression. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 645-648.	0.7	21
84	Reduced inattention and hyperactivity and improved cognition after marine oil extract (PCSO-524®) supplementation in children and adolescents with clinical and subclinical symptoms of attention-deficit hyperactivity disorder (ADHD): a randomised, double-blind, placebo-controlled trial. <i>Psychopharmacology</i> , 2017, 234, 403-420.	1.5	21
85	Exploring the Effect of Lactium, and Zizyphus Complex on Sleep Quality: A Double-Blind, Randomized Placebo-Controlled Trial. <i>Nutrients</i> , 2017, 9, 154.	1.7	21
86	Therapeutic Opportunities for Food Supplements in Neurodegenerative Disease and Depression. <i>Frontiers in Nutrition</i> , 2021, 8, 669846.	1.6	21
87	Clinical use of nutraceuticals in the adjunctive treatment of depression in mood disorders. <i>Australasian Psychiatry</i> , 2017, 25, 369-372.	0.4	20
88	Participant experiences from chronic administration of a multivitamin versus placebo on subjective health and wellbeing: a double-blind qualitative analysis of a randomised controlled trial. <i>Nutrition Journal</i> , 2012, 11, 110.	1.5	19
89	EPA and DHA as markers of nutraceutical treatment response in major depressive disorder. <i>European Journal of Nutrition</i> , 2020, 59, 2439-2447.	1.8	19
90	S-Adenosylmethionine (SAME) monotherapy for depression: an 8-week double-blind, randomised, controlled trial. <i>Psychopharmacology</i> , 2020, 237, 209-218.	1.5	19

#	ARTICLE	IF	CITATIONS
91	Plant-based Medicines (Phytoceuticals) in the Treatment of Psychiatric Disorders: A Meta-review of Meta-analyses of Randomized Controlled Trials: Les médicaments à base de plantes (phytoceutiques) dans le traitement des troubles psychiatriques: une méta-revue des méta-analyses d'essais randomisés contrôlés. Canadian Journal of Psychiatry, 2021, 66, 849-862.	0.9	19
92	Genetic Technologies for Herbal Medicines in Psychiatry. Phytotherapy Research, 2012, 26, 522-527.	2.8	17
93	Mind-Body Medicine for Schizophrenia and Psychotic Disorders. Clinical Schizophrenia and Related Psychoses, 2013, 7, 138-148.	1.4	17
94	The Effects of Multivitamin Supplementation on Diurnal Cortisol Secretion and Perceived Stress. Nutrients, 2013, 5, 4429-4450.	1.7	17
95	Adjunctive nutrients in first-episode psychosis: A systematic review of efficacy, tolerability and neurobiological mechanisms. Microbial Biotechnology, 2018, 12, 774-783.	0.9	17
96	The relationship between dietary quality, serum brain-derived neurotrophic factor (BDNF) level, and the Val66met polymorphism in predicting depression. Nutritional Neuroscience, 2019, 22, 513-521.	1.5	17
97	Prevalence and predictors of herbal medicine use in adults experiencing anxiety: A critical review of the literature. Advances in Integrative Medicine, 2015, 2, 38-48.	0.4	16
98	The Therapeutic Potential of Mangosteen Pericarp as an Adjunctive Therapy for Bipolar Disorder and Schizophrenia. Frontiers in Psychiatry, 2019, 10, 115.	1.3	16
99	Medicinal cannabis and driving: the intersection of health and road safety policy. International Journal of Drug Policy, 2021, 97, 103307.	1.6	16
100	Effects of cannabis ingestion on endometriosis-associated pelvic pain and related symptoms. PLoS ONE, 2021, 16, e0258940.	1.1	16
101	Comparative Use of Complementary Medicine, Allied Health, and Manual Therapies by Middle-Aged and Older Australian Women. Journal of Women and Aging, 2010, 22, 273-282.	0.5	15
102	Effects of multivitamin, mineral and herbal supplement on cognition in younger adults and the contribution of B group vitamins. Human Psychopharmacology, 2014, 29, 73-82.	0.7	15
103	An adjunctive antidepressant nutraceutical combination in treating major depression: Study protocol, and clinical considerations. Advances in Integrative Medicine, 2015, 2, 49-55.	0.4	15
104	Erythrocyte polyunsaturated fatty acid composition is associated with depression and FADS genotype in Caucasians. Nutritional Neuroscience, 2018, 21, 589-601.	1.5	15
105	Nutrient and genetic biomarkers of nutraceutical treatment response in mood and psychotic disorders: a systematic review. Nutritional Neuroscience, 2021, 24, 279-295.	1.5	14
106	Pathophysiology of Major Depression by Clinical Stages. Frontiers in Psychology, 2021, 12, 641779.	1.1	14
107	Psychedelic medicines for mood disorders: current evidence and clinical considerations. Current Opinion in Psychiatry, 2022, 35, 22-29.	3.1	14
108	Harnessing the Four Elements for Mental Health. Frontiers in Psychiatry, 2019, 10, 256.	1.3	13



#	ARTICLE	IF	CITATIONS
109	Pilot-Testing of "Healthy Body Healthy Mind" An Integrative Lifestyle Program for Patients With a Mental Illness and Co-morbid Metabolic Syndrome. <i>Frontiers in Psychiatry</i> , 2019, 10, 91.	1.3	13
110	Lifestyle medicine for anxiety symptoms: A meta-analysis of randomized controlled trials. <i>Journal of Affective Disorders</i> , 2022, 310, 354-368.	2.0	13
111	Chinese herbal medicine for sleep disorders: Poor methodology restricts any clear conclusion. <i>Sleep Medicine Reviews</i> , 2012, 16, 493-495.	3.8	12
112	Zao Ren An Shen for insomnia: a systematic review with meta-analysis. <i>Sleep Medicine</i> , 2020, 69, 41-50.	0.8	12
113	A multi-national, multi-disciplinary Delphi consensus study on using omega-3 polyunsaturated fatty acids (n-3 PUFAs) for the treatment of major depressive disorder. <i>Journal of Affective Disorders</i> , 2020, 265, 233-238.	2.0	12
114	Smartphone-delivered multicomponent lifestyle medicine intervention for depressive symptoms: A randomized controlled trial.. <i>Journal of Consulting and Clinical Psychology</i> , 2021, 89, 970-984.	1.6	12
115	Adjunctive low-dose docosahexaenoic acid (DHA) for major depression: An open-label pilot trial. <i>Nutritional Neuroscience</i> , 2018, 21, 224-228.	1.5	11
116	Diet quality, dietary inflammatory index and body mass index as predictors of response to adjunctive N-acetylcysteine and mitochondrial agents in adults with bipolar disorder: A sub-study of a randomised placebo-controlled trial. <i>Australian and New Zealand Journal of Psychiatry</i> , 2020, 54, 159-172.	1.3	11
117	Herbal medicines and phytochemicals for obsessive-compulsive disorder. <i>Phytotherapy Research</i> , 2020, 34, 1889-1901.	2.8	11
118	A Systematic Review of Nutraceuticals for the Treatment of Bipolar Disorder. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 262-273.	0.9	11
119	Potential biomarkers of major depression diagnosis and chronicity. <i>PLoS ONE</i> , 2021, 16, e0257251.	1.1	11
120	Implementation of psychiatric-focused lifestyle medicine programs in Asia. <i>Asia-Pacific Psychiatry</i> , 2015, 7, 345-354.	1.2	9
121	Physical Activity as a Predictor of Clinical Trial Outcomes in Bipolar Depression: A Subanalysis of a Mitochondrial-Enhancing Nutraceutical Randomized Controlled Trial. <i>Canadian Journal of Psychiatry</i> , 2020, 65, 306-318.	0.9	9
122	A randomized controlled trial investigating the effects of PCSO-524®, a patented oil extract of the New Zealand green lipped mussel ( <i>Perna canaliculus</i> ), on the behaviour, mood, cognition and neurophysiology of children and adolescents (aged 6-14 years) experiencing clinical and sub-clinical levels of hyperactivity and inattention: study protocol ACTRN12610000978066. <i>Nutrition Journal</i> , 2013, 12, 100.	1.5	8
123	Student attitudes towards clinical teaching resources in complementary medicine: a focus group examination of Australian naturopathic medicine students. <i>Health Information and Libraries Journal</i> , 2014, 31, 123-132.	1.3	8
124	Participant Characteristics as Modifiers of Response to N-Acetyl Cysteine (NAC) in Obsessive-Compulsive Disorder. <i>Clinical Psychological Science</i> , 2016, 4, 1104-1111.	2.4	8
125	Do reductions in ghrelin contribute towards antipsychotic-induced weight gain?. <i>Schizophrenia Research</i> , 2019, 210, 301-302.	1.1	8
126	Efficacy of adjunctive <i>Garcinia mangostana</i> Linn (mangosteen) pericarp for bipolar depression: study protocol for a proof-of-concept trial. <i>Revista Brasileira De Psiquiatria</i> , 2019, 41, 245-253.	0.9	8



#	ARTICLE	IF	CITATIONS
127	The effect of vitamin C supplementation on mood status in adults: a systematic review and meta-analysis of randomized controlled clinical trials. <i>General Hospital Psychiatry</i> , 2021, 71, 36-42.	1.2	8
128	Naturopathic medicine for treating self-reported depression and anxiety: An observational pilot study of naturalistic practice. <i>Advances in Integrative Medicine</i> , 2014, 1, 87-92.	0.4	6
129	Nutraceuticals and nutritional supplements for the treatment of bipolar disorder: protocol for a systematic review. <i>BMJ Open</i> , 2019, 9, e025640.	0.8	5
130	Effects of a group-based lifestyle medicine for depression: A pilot randomized controlled trial. <i>PLoS ONE</i> , 2021, 16, e0258059.	1.1	5
131	Clinical depression: an evidence-based integrative complementary medicine treatment model. <i>Alternative Therapies in Health and Medicine</i> , 2011, 17, 26-37.	0.0	5
132	N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 117, 110550.	2.5	5
133	A Case of Acute Problem Gambling Associated With Agomelatine. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 153-155.	0.7	4
134	The Relationship between Oxidative Stress and Anxiety in a Healthy Older Population. <i>Experimental Aging Research</i> , 2021, 47, 322-346.	0.6	4
135	Omega-3 Fatty Acid Supplementation for Perinatal Depression and Other Subpopulations?. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	1.1	4
136	Conditional Probability of Response or Nonresponse of Placebo Compared With Antidepressants or St John's Wort in Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 827-830.	0.7	3
137	Effects of <i>Bacopa monnieri</i> (CDRI-08 <sup>®</sup> ) in a population of males exhibiting inattention and hyperactivity aged 6 to 14 years: A randomized, double-blind, placebo-controlled trial. <i>Phytotherapy Research</i> , 2022, 36, 996-1012.	2.8	3
138	Disruptive innovation in psychiatry. <i>Annals of the New York Academy of Sciences</i> , 2022, 1512, 5-9.	1.8	3
139	Legalization of Psychedelic Substances. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 2434.	3.8	3
140	Quality control of cannabis inflorescence and oil products: Response factors for the cost-efficient determination of ten cannabinoids by HPLC. <i>Talanta Open</i> , 2022, 5, 100112.	1.7	3
141	Aripiprazole as augmentation therapy in bipolar patients with current minor or subsyndromal mood symptoms. <i>International Journal of Bipolar Disorders</i> , 2013, 1, 4.	0.8	2
142	Videoconference mind-body group therapy in a public mental health setting: a pilot study. <i>Journal of Technology in Behavioral Science</i> , 2016, 1, 37-42.	1.3	2
143	Herbal Anxiolytics with Sedative Actions. , 2017, , 11-31.		2
144	Potential mental and physical benefits of supplementation with a high-dose, B-complex multivitamin/mineral supplement: What is the evidence?. <i>Nutricion Hospitalaria</i> , 2021, 38, 1277-1286.	0.2	2

#	ARTICLE	IF	CITATIONS
145	Mixed Methods Thematic Analysis of a Randomised Controlled Trial of Adjunctive Mitochondrial Agents for Bipolar Depression. <i>Clinical Psychopharmacology and Neuroscience</i> , 2022, 20, 300-310.	0.9	2
146	Pyroluria: Fact or Fiction?. <i>Journal of Alternative and Complementary Medicine</i> , 2021, 27, 407-415.	2.1	1
147	Lifestyle Medicine for the Prevention and Treatment of Depression. , 2016, , 281-289.		0
148	Treatments for Comorbid Anxiety and Mood Disorders. , 2017, , 103-119.		0
149	Potential Herbal Anxiolytics. , 2017, , 139-152.		0
150	Alternative Treatments for Obsessive-Compulsive Disorder: Nutraceuticals and Lifestyle Interventions. , 2019, , 292-306.		0
151	Mental health and complementary and alternative medicine. , 2012, , 79-86.		0
152	Is insomnia disorder associated with time in bed extension?. <i>Sleep Science</i> , 2020, 13, 215-219.	0.4	0
153	Assessing dietary, exercise, and non-pharmacological modalities within psychiatric hospitals. <i>General Hospital Psychiatry</i> , 2022, 76, 31-35.	1.2	0
154	Nutraceuticals and phytochemicals for treating psychiatric disorders: a synopsis of the WFSBP and CANMAT 2022 clinician guidelines. <i>Jornal Brasileiro De Psiquiatria</i> , 2022, 71, 69-70.	0.2	0